Gut Microbiota and Atherosclerosis: Integrative Multi-Omics and Mechanistic Insights Authors: Jiahuan Helen He, Hanwen Wang, Eric Qiu, Qibin Qi, Zheng Wang Published: 2025 ABSTRACT Purpose of ReviewThis review synthesizes and discusses evidence from metagenomics, metabolomics, and proteomics on gut microbiome alterations in atherosclerotic cardiovascular disease (ACVD), with carotid atherosclerosis (CAS) serving as an example.Recent FindingsEvidence on gut microbial α-diversity and β-diversity was mixed and differs by disease status. Pro-inflammatory/pathogenic gut bacterial taxa (e.g., Escherichia coli, Klebsiella spp., Streptococcus spp., and Ruminococcus gnavus) were often enriched in patients with ACVD or CAS, whereas short-chain fatty acid (SCFA) producers (e.g., Faecalibacterium prausnitzii, Roseburia spp., Bacteroides spp., and Eubacterium eligens) were depleted. Targeted and untargeted metabolomics implicated multiple microbial-derived metabolites in relation to ACVD and CAS, including trimethylamine N-oxide, short-chain fatty acids, bile acids, lipopolysaccharides, phenylacetylglutamine, indole-3-propionate and imidazole propionate.SummaryGut dysbiosis contributes to ACVD or CAS possibly via metabolite-mediated effects on endothelial function, inflammation, and lipid metabolism. Future research prioritizing longitudinal and interventional studies integrating microbial metagenomics with host multi-omics are needed to elucidate causal pathways and identify clinically actionable targets. Introduction Atherosclerotic cardiovascular disease (ACVD) remains the leading cause of global morbidity and mortality. In 2023, ACVD accounted for a substantial global health burden, with ischemic heart disease and ischemic stroke representing the two most common causes of cardiovascular death, causing approximately 8.9 million and 3.3 million deaths, respectively [1]. Carotid atherosclerosis (CAS), the buildup of plaque in the carotid arteries that transport blood to the head and brain, is a manifestation of systemic ACVD [2]. CAS is usually assessed by non-invasive carotid ultrasound imaging including the measurement of carotid intima-media thickness and the detection and quantification of carotid arterial plaque (presence, thickness, area, or volume) [3]. In 2020, the prevalence of increased carotid intima-media thickness and presence of carotid plaque was around 28% and 21%, respectively [4]. CAS can contribute directly to ischemic stroke when a carotid plaque ruptures, and the plaque fragments or thrombi can embolize into cerebral blood vessels, leading to ischemic stroke or transient ischemic attack [2]. The pathophysiology of CAS involves endothelial dysfunction, vascular smooth muscle dysregulation, abnormal lipid accumulation, and chronic vascular inflammation [2]. Traditional risk factors such as older age, dyslipidemia, high blood pressure, treated for hypertension, diabetes, obesity, and smoking only partially explain the variability in plaque burden [5, 6]. Prior research has shown that these factors explain less than 20% of the variability in carotid plaque area, and even after incorporating socioeconomic determinants, the proportion of variability explained improved only marginally [7]. This suggests that additional non-traditional factors may play a role in determining individual susceptibility to atherosclerosis. Recently, gut microbiota has emerged as another potential player in atherogenesis [8, 9]. Gut dysbiosis, or imbalance in gut microbial composition, has been linked to the generation of pro-atherogenic metabolites such as trimethylamine N-oxide (TMAO), as well as the reduction of protective short-chain fatty acids (SCFAs) [8, 9]. This review focuses on ACVD, using CAS as an example, given the direct clinical relevance of CAS to stroke, where it accounts for 15%-20% of the ischemic stroke cases [10], as well as its utility to predict the risk of cardiovascular disease [11]. We summarize current evidence on gut microbiota alterations in patients with subclinical or clinical ACVD, discuss the potential mechanism, and highlight key research gaps and future directions for leveraging gut microbiota to improve CAS risk assessment and therapy. A systematic search was performed in PubMed covering studies published from January 2010 through October 2025. Search terms included “gut microbiota”, “microbiome”, “atherosclerosis”, “carotid atherosclerosis’, and “stroke”. We identified research articles through a manual review process of the selected publications. Alterations of Gut Microbiota in ACVD Patients In healthy adults, Bacteroidetes and Firmicutes are the major bacterial phyla in the gut accounting for more than 90% of the total bacterial taxa, followed by a smaller portion of phyla Proteobacteria and Actinobacteria [12]. Accumulating evidence suggests that patients with CAS or broader AVCD have gut microbial communities that differ from those of healthy individuals. These differences are not only observed in overall microbial diversity but also in the relative abundance of specific taxa that may be pro- or anti-atherogenic. α-Diversity Findings on microbial richness and evenness in ACVD, including CAS, are inconsistent. Most studies reported no significant differences in microbial richness or evenness between individuals with atherosclerotic conditions and controls. However, a few studies such as Haak et al. (2020) [13] observed a reduction in α-diversity among patients with stroke (primarily ischemic stroke), implying a loss of microbial complexity in advanced cerebrovascular disease. Some evidence also indicates that specific cardiometabolic or clinical factors may correlate with α-diversity. For instance, Li R.J. et al. (2021) [14] reported that α-diversity was positively associated with blood pressure and follicle-stimulating hormone but negatively correlated with uric acid and liver enzyme gamma-glutamyl transferase (GGT) (Table 1).Table 1Overview of gut microbiome alterations in relation to atherosclerosisAuthor (Year)LocationSample SizeOutcomeStudy designMethodsIncreased Relative Abundance in Group with clinical/subclinical/risk factors of atherosclerosisDecreased Relative Abundance in Group with clinical/subclinical/risk factors of atherosclerosisOther Findings (Diversity, Metabolomics, Transcriptomics, Associations)Chen et al., 2021 [15]China31 CAS, 51 controlsCASCase–controlMetagenomic shotgun sequencingBacteroides eggerthii, Escherichia coli, Klebsiella pneumoniaeParabacteroides unclassified, Prevotella copri, Bacteroides spp. 3_1_19, Haemophilus parainfluenzaeNo significant difference in α- or β-diversity observed between groupsJi et al., 2021 [16]China32 CAS, 32 controlsCASCase–control16S rDNA sequencingAcidaminococcus, Christensenella, LactobacillusAnaerostipes, Fusobacterium, Gemella, Parvimonas, Romboutsia, Clostridium XVIII/XIVa/XIVbIncreased phenylacetylglutamine (PAGln);Increased FABP4 gene expression;FABP4 was positively correlated with Acidaminococcus and PAGln;FABP4 was negatively correlated with ethanolamineNo significant difference in α-diversity, but β-diversity was significantly different between groupsJie et al., 2017 [17]China218 ACVD, 187 controlsACVDCase–controlMetagenomic shotgun sequencingEscherichia coli, Klebsiella spp., Enterobacter aerogenes, Streptococcus spp., Lactobacillus salivarius, Solobacterium moorei, Atopobium parvulum, Ruminococcus gnavus, Eggerthella lentaRoseburia intestinalis, Faecalibacterium prausnitzii, Bacteroides spp., Prevotella copri, Alistipes shahiiStreptococcus spp. negatively correlated with Bacteroides spp.;Klebsiella oxytoca correlated with aspartate aminotransferase (AST), creatine kinase MB;Faecalibacterium prausnitzii inversely correlated with uric acidNo significant difference in α- or β-diversity observed between groupsHuang et al., 2023 [18]Southern China45 at risk of stroke, 15 controlsStrokeCase–control16S rRNA sequencingAnaerostipes, Clostridium XIVb, Flavonifractor–No significant difference in α-diversity, but β-diversity was significantly different between groupsKarlsson et al., 2012 [19]Sweden12 CAS, 13 controlsCASCase–controlMetagenomic shotgun sequencingCollinsellaRoseburia, Eubacterium–Szabo et al., 2021 [20]Hungary14 monozygotic twins with discordant carotid intima-media thicknessCarotid intima-media thickness,Twin study16S rRNA sequencingFirmicutes, higher Firmicutes/Bacteroidetes ratioPrevotellaceaeNo α-diversity difference between groups;Higher risk of carotid intima-media thickness in high Firmicutes groupZhu et al., 2022 [21]Rural China569 older adults with asymptomatic subclinical atherosclerosisAsymptomatic subclinical atherosclerosisCross-sectionalMetagenomic shotgun sequencingLibanicoccusFaecalicatenaHealthier lifestyle led to lowered risk of CAS via Alistipes, Oligella, Prevotella;Blood chemistry, arterial stiffness, bone mass density, and carotid ultrasonographic measurements were predictors of phylum-level α-diversity;Heart function, disease status, demographic data, socio-economic status, and arterial stiffness were found to be strongly associated with β-diversityBaragetti et al., 2021 [22]Northern Milan144 with subclinical CAS, 201 controlsSubclinical CASCross-sectional16S rRNA sequencing and metagenomic shotgun sequencingEscherichia, Shigella, Streptococcus (S. salivarius, S. parasanguinis, S. anginosus), OscillospiraBacteroides (B. uniformis, B. thetaiotaomicron)No significant difference in α-diversity;β-diversity was significantly different between groupsStø et al., 2022 [23]Norway43 CAS, 38 controlsCASCase–control16S rRNA sequencingAnaerotruncus, Ruminococcus gnavus, Lachnospiraceae CAG_56Lachnospiraceae UCG_003, Eubacterium eligens, CoprococcusMixed pattern among butyrate-producing taxa;No difference in top 10 genera between the two groups;No significant difference in α- or β-diversity observed between groupsLi R.J. et al., 2021 [14]China102 treatment-naïve CAS + metabolic dysfunctions; 36 treatment-naïve metabolic dysfunctionsCASCase–controlMetagenomic shotgun sequencingClostridium bolteae, Tyzzerella nexilis, Ruminococcus gnavus, Blautia hansenii, Atopobium parvulum, Solobacterium mooreiEubacterium eligens, Faecalibacterium prausnitzii, Ruminococcus lactarisPositive correlation between higher levels of gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), total bilirubin with pathogenic taxa; E. eligens inversely correlated with liver dysfunction markers;Blood pressure and follicle-stimulating hormone were positively correlated with α-diversity, while uric acid and GGT were negatively correlated with α-diversityNo significant difference in α-diversity between groupsLi H. et al., 2020 [24]China79 cerebral infarction, 98 controlsCerebral infarctionCase–control16S rRNA sequencingProteobacteria, ActinobacteriaFirmicutes, BacteroidetesNo significant difference in α- or β-diversity observed between groupsHaak et al., 2020 [13]Netherlands349 stroke (287 ischemic, 37 hemorrhagic), 51 controlsStrokeCase–control16S rRNA sequencingEscherichia/Shigella, Peptoniphilus, Ezakiella, EnterococcusBlautia, Subdoligranulum, BacteroidesDecreased α- and β-diversity in patients with stroke;Controls and transient ischemic attack without stroke had higher SCFA-producing taxaTan et al., 2020 [25]China140 stroke, 92 controlsStrokeCase–control16S rRNA sequencingLactobacillaceae, Akkermansia, Enterobacteriaceae, PorphyromonadaceaeRoseburia, Bacteroides, Lachnospiraceae, Faecalibacterium, Blautia, AnaerostipesHigher stroke severity was associated with fewer SCFA producers, more pro-inflammatory taxaDifference in β-diversity was observed between groupsWang et al., 2022 [26]United States361 women with or at high risk of HIV (67% HIV positive)737 women and men with or at high risk of HIV for lipidomic and metabolomic profiling112 participants developed carotid artery plaquesCASCross-sectional16S rRNA sequencingFusobacterium and ProteusOdoribacterFusobacterium and Proteus were positively correlated with a broad set of plasma lipid and metabolite profiles, which grouped into 8 distinct co-expression network modulesTwo lipid modules, one comprised of lysophosphatidylcholines (LPCs) and lysophosphatidylethanolamines (LPEs), and another enriched in diglyycerides (DGs), were significantly associated with a higher risk of carotid artery plaque formationPhospholipases A1 and A2 were identified as key enzymes in LPC and LPE productionNo significant difference in α- or β-diversity observed between groupsWang et al., 2023 [27]United States433 women with or at high risk of HIV (65% HIV positive)Carotid artery plaqueCross-sectionalMetagenomic shotgun sequencingFusobacterium nucleatumRoseburia hominis, Roseburia inulinivorans, Johnsonella ignava, Odoribacter splanchnicus, Clostridium saccharolyticumIncreased abundance of F. nucleatum was associated with carotid plaque and higher levels of CXCL9 (inflammatory marker);Decreased abundance of Roseburia spp. and others inversely associated with CX3CL1;Plasma metabolite imidazole-propionate positively linked with plaque and inflammationNo significant difference in α- or β-diversity observed between groups Table 1Overview of gut microbiome alterations in relation to atherosclerosisAuthor (Year)LocationSample SizeOutcomeStudy designMethodsIncreased Relative Abundance in Group with clinical/subclinical/risk factors of atherosclerosisDecreased Relative Abundance in Group with clinical/subclinical/risk factors of atherosclerosisOther Findings (Diversity, Metabolomics, Transcriptomics, Associations)Chen et al., 2021 [15]China31 CAS, 51 controlsCASCase–controlMetagenomic shotgun sequencingBacteroides eggerthii, Escherichia coli, Klebsiella pneumoniaeParabacteroides unclassified, Prevotella copri, Bacteroides spp. 3_1_19, Haemophilus parainfluenzaeNo significant difference in α- or β-diversity observed between groupsJi et al., 2021 [16]China32 CAS, 32 controlsCASCase–control16S rDNA sequencingAcidaminococcus, Christensenella, LactobacillusAnaerostipes, Fusobacterium, Gemella, Parvimonas, Romboutsia, Clostridium XVIII/XIVa/XIVbIncreased phenylacetylglutamine (PAGln);Increased FABP4 gene expression;FABP4 was positively correlated with Acidaminococcus and PAGln;FABP4 was negatively correlated with ethanolamineNo significant difference in α-diversity, but β-diversity was significantly different between groupsJie et al., 2017 [17]China218 ACVD, 187 controlsACVDCase–controlMetagenomic shotgun sequencingEscherichia coli, Klebsiella spp., Enterobacter aerogenes, Streptococcus spp., Lactobacillus salivarius, Solobacterium moorei, Atopobium parvulum, Ruminococcus gnavus, Eggerthella lentaRoseburia intestinalis, Faecalibacterium prausnitzii, Bacteroides spp., Prevotella copri, Alistipes shahiiStreptococcus spp. negatively correlated with Bacteroides spp.;Klebsiella oxytoca correlated with aspartate aminotransferase (AST), creatine kinase MB;Faecalibacterium prausnitzii inversely correlated with uric acidNo significant difference in α- or β-diversity observed between groupsHuang et al., 2023 [18]Southern China45 at risk of stroke, 15 controlsStrokeCase–control16S rRNA sequencingAnaerostipes, Clostridium XIVb, Flavonifractor–No significant difference in α-diversity, but β-diversity was significantly different between groupsKarlsson et al., 2012 [19]Sweden12 CAS, 13 controlsCASCase–controlMetagenomic shotgun sequencingCollinsellaRoseburia, Eubacterium–Szabo et al., 2021 [20]Hungary14 monozygotic twins with discordant carotid intima-media thicknessCarotid intima-media thickness,Twin study16S rRNA sequencingFirmicutes, higher Firmicutes/Bacteroidetes ratioPrevotellaceaeNo α-diversity difference between groups;Higher risk of carotid intima-media thickness in high Firmicutes groupZhu et al., 2022 [21]Rural China569 older adults with asymptomatic subclinical atherosclerosisAsymptomatic subclinical atherosclerosisCross-sectionalMetagenomic shotgun sequencingLibanicoccusFaecalicatenaHealthier lifestyle led to lowered risk of CAS via Alistipes, Oligella, Prevotella;Blood chemistry, arterial stiffness, bone mass density, and carotid ultrasonographic measurements were predictors of phylum-level α-diversity;Heart function, disease status, demographic data, socio-economic status, and arterial stiffness were found to be strongly associated with β-diversityBaragetti et al., 2021 [22]Northern Milan144 with subclinical CAS, 201 controlsSubclinical CASCross-sectional16S rRNA sequencing and metagenomic shotgun sequencingEscherichia, Shigella, Streptococcus (S. salivarius, S. parasanguinis, S. anginosus), OscillospiraBacteroides (B. uniformis, B. thetaiotaomicron)No significant difference in α-diversity;β-diversity was significantly different between groupsStø et al., 2022 [23]Norway43 CAS, 38 controlsCASCase–control16S rRNA sequencingAnaerotruncus, Ruminococcus gnavus, Lachnospiraceae CAG_56Lachnospiraceae UCG_003, Eubacterium eligens, CoprococcusMixed pattern among butyrate-producing taxa;No difference in top 10 genera between the two groups;No significant difference in α- or β-diversity observed between groupsLi R.J. et al., 2021 [14]China102 treatment-naïve CAS + metabolic dysfunctions; 36 treatment-naïve metabolic dysfunctionsCASCase–controlMetagenomic shotgun sequencingClostridium bolteae, Tyzzerella nexilis, Ruminococcus gnavus, Blautia hansenii, Atopobium parvulum, Solobacterium mooreiEubacterium eligens, Faecalibacterium prausnitzii, Ruminococcus lactarisPositive correlation between higher levels of gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), total bilirubin with pathogenic taxa; E. eligens inversely correlated with liver dysfunction markers;Blood pressure and follicle-stimulating hormone were positively correlated with α-diversity, while uric acid and GGT were negatively correlated with α-diversityNo significant difference in α-diversity between groupsLi H. et al., 2020 [24]China79 cerebral infarction, 98 controlsCerebral infarctionCase–control16S rRNA sequencingProteobacteria, ActinobacteriaFirmicutes, BacteroidetesNo significant difference in α- or β-diversity observed between groupsHaak et al., 2020 [13]Netherlands349 stroke (287 ischemic, 37 hemorrhagic), 51 controlsStrokeCase–control16S rRNA sequencingEscherichia/Shigella, Peptoniphilus, Ezakiella, EnterococcusBlautia, Subdoligranulum, BacteroidesDecreased α- and β-diversity in patients with stroke;Controls and transient ischemic attack without stroke had higher SCFA-producing taxaTan et al., 2020 [25]China140 stroke, 92 controlsStrokeCase–control16S rRNA sequencingLactobacillaceae, Akkermansia, Enterobacteriaceae, PorphyromonadaceaeRoseburia, Bacteroides, Lachnospiraceae, Faecalibacterium, Blautia, AnaerostipesHigher stroke severity was associated with fewer SCFA producers, more pro-inflammatory taxaDifference in β-diversity was observed between groupsWang et al., 2022 [26]United States361 women with or at high risk of HIV (67% HIV positive)737 women and men with or at high risk of HIV for lipidomic and metabolomic profiling112 participants developed carotid artery plaquesCASCross-sectional16S rRNA sequencingFusobacterium and ProteusOdoribacterFusobacterium and Proteus were positively correlated with a broad set of plasma lipid and metabolite profiles, which grouped into 8 distinct co-expression network modulesTwo lipid modules, one comprised of lysophosphatidylcholines (LPCs) and lysophosphatidylethanolamines (LPEs), and another enriched in diglyycerides (DGs), were significantly associated with a higher risk of carotid artery plaque formationPhospholipases A1 and A2 were identified as key enzymes in LPC and LPE productionNo significant difference in α- or β-diversity observed between groupsWang et al., 2023 [27]United States433 women with or at high risk of HIV (65% HIV positive)Carotid artery plaqueCross-sectionalMetagenomic shotgun sequencingFusobacterium nucleatumRoseburia hominis, Roseburia inulinivorans, Johnsonella ignava, Odoribacter splanchnicus, Clostridium saccharolyticumIncreased abundance of F. nucleatum was associated with carotid plaque and higher levels of CXCL9 (inflammatory marker);Decreased abundance of Roseburia spp. and others inversely associated with CX3CL1;Plasma metabolite imidazole-propionate positively linked with plaque and inflammationNo significant difference in α- or β-diversity observed between groups Overview of gut microbiome alterations in relation to atherosclerosis Increased phenylacetylglutamine (PAGln); Increased FABP4 gene expression; FABP4 was positively correlated with Acidaminococcus and PAGln; FABP4 was negatively correlated with ethanolamine No significant difference in α-diversity, but β-diversity was significantly different between groups Streptococcus spp. negatively correlated with Bacteroides spp.; Klebsiella oxytoca correlated with aspartate aminotransferase (AST), creatine kinase MB; Faecalibacterium prausnitzii inversely correlated with uric acid No significant difference in α- or β-diversity observed between groups No α-diversity difference between groups; Higher risk of carotid intima-media thickness in high Firmicutes group Healthier lifestyle led to lowered risk of CAS via Alistipes, Oligella, Prevotella; Blood chemistry, arterial stiffness, bone mass density, and carotid ultrasonographic measurements were predictors of phylum-level α-diversity; Heart function, disease status, demographic data, socio-economic status, and arterial stiffness were found to be strongly associated with β-diversity No significant difference in α-diversity; β-diversity was significantly different between groups Mixed pattern among butyrate-producing taxa; No difference in top 10 genera between the two groups; No significant difference in α- or β-diversity observed between groups Positive correlation between higher levels of gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), total bilirubin with pathogenic taxa; E. eligens inversely correlated with liver dysfunction markers; Blood pressure and follicle-stimulating hormone were positively correlated with α-diversity, while uric acid and GGT were negatively correlated with α-diversity No significant difference in α-diversity between groups Decreased α- and β-diversity in patients with stroke; Controls and transient ischemic attack without stroke had higher SCFA-producing taxa Higher stroke severity was associated with fewer SCFA producers, more pro-inflammatory taxa Difference in β-diversity was observed between groups 361 women with or at high risk of HIV (67% HIV positive) 737 women and men with or at high risk of HIV for lipidomic and metabolomic profiling 112 participants developed carotid artery plaques Fusobacterium and Proteus were positively correlated with a broad set of plasma lipid and metabolite profiles, which grouped into 8 distinct co-expression network modules Two lipid modules, one comprised of lysophosphatidylcholines (LPCs) and lysophosphatidylethanolamines (LPEs), and another enriched in diglyycerides (DGs), were significantly associated with a higher risk of carotid artery plaque formation Phospholipases A1 and A2 were identified as key enzymes in LPC and LPE production No significant difference in α- or β-diversity observed between groups Increased abundance of F. nucleatum was associated with carotid plaque and higher levels of CXCL9 (inflammatory marker); Decreased abundance of Roseburia spp. and others inversely associated with CX3CL1; Plasma metabolite imidazole-propionate positively linked with plaque and inflammation No significant difference in α- or β-diversity observed between groups β-Diversity Several studies have reported significant alterations in β-diversity, indicating differences in microbial community composition between patients with ACVD or CAS and controls. Ji et al. (2021) [16], Huang et al. (2023) [18], and Baragetti et al. (2021) [22] consistently demonstrated, despite of no between-group difference in α-diversity, distinct clustering of gut microbiota compositions based on disease status using UniFrac or Bray–Curtis metrics. These results indicate that ACVD is associated with compositional remodeling of the gut microbial environment, even when within-sample diversity is maintained. However, many other studies, such as those by Chen et al. (2021) [15], Jie et al. (2017) [17], and Stø et al. (2022) [23], etc. found no difference in β-diversity between individuals with ACVD/CAS and those without, suggesting that alterations in specific taxa, rather than changes in whole community, may better capture atherosclerotic disease-associated dysbiosis (Table 1). Specific Microbial Taxa Associated with Clinical/Subclinical ACVD Several taxa consistently differ between patients with ACVD/CAS and controls (Table 1). Enrichment of pro-inflammatory and pathogenic taxa, including Escherichia coli, Klebsiella spp., Streptococcus spp., and Ruminococcus gnavus, were repeatedly observed in ACVD and CAS population. These taxa are known for their roles in inflammation and atherosclerosis promotion owing to their lipopolysaccharide (LPS) [28, 29] In contrast, SCFA-producing and anti-inflammatory taxa such as Faecalibacterium prausnitzii, Roseburia spp., Bacteroides spp., and Eubacterium eligens were consistently depleted in patients with ACVD or CAS specifically [17, 30, 31]. Reduced abundance of these taxa may impair butyrate synthesis, jeopardizing gut barrier integrity and promoting systemic inflammation. In addition, lower abundance of Prevotella species has been consistently observed in individuals with ACVD/CAS across studies. Experimental evidence suggests that certain Bacteroides species, such as B. vulgatus and B. dorei, may exert protective effects against atherosclerosis by reducing gut-derived LPS production [32]. Although Prevotella has been implicated in atherosclerosis through its potential to generate trimethylamine, its overall depletion in patient groups compared with controls suggests that its role may be context-dependent and influenced by host metabolic or dietary factors [33]. Collectively, these findings highlight that atherosclerosis is associated with selective enrichment of pro-inflammatory taxa and depletion of anti-inflammatory taxa. Nonetheless, there was also substantial variability in findings across studies, likely due to differences in geography, diet, lifestyle, and disease stage (e.g., subclinical versus clinical ACVD or stroke). Potential Mechanisms of Gut Microbiome Alterations, their Interactions with Other Multi-Omics Layers, and the Development of ACVD Gut Microbiome and Metabolomics Current metabolomics studies demonstrate that gut-derived metabolites are strongly linked to atherosclerosis burden and its underlying biological mechanisms, with evidence from both untargeted metabolomics and targeted analyses of specific microbial metabolites. In a landmark metabolomics study, Wang et al. (2011) [34] first demonstrated a potential causal link between gut microbiota-derived metabolites and CVD using an unbiased plasma metabolomics approach. By profiling over 2,000 small molecules, they identified that choline, betaine, and TMAO strongly predicted risk of CVD, including myocardial infarction and stroke, independent of traditional risk factors. Experimental validation in mice revealed that dietary supplementation with choline or TMAO markedly enhanced atherosclerotic plaque formation, whereas suppression of gut microbiota using antibiotics abolished this effect. In a trans-omics study of Chinese adults, Li et al. (2021) [14] integrated stool metagenomics, serum and urine metabolomics, and clinical data, showing that metabolite-based models outperformed microbial taxonomy alone for discriminating CAS. For example, adding urine metabolite ME71, which was lower in CAS patients, improved classification performance to an area under the curve of 0.78, indicating that metabolites may more directly capture plaque-related biological activity than gut microbial composition alone. A multi-omics study from the MACS/WIHS Combined Cohort (MWCCS) reported positive associations of Fusobacterium and Proteus with carotid plaque, and an inverse correlation for butyrate-producing Odoribacter. Network-based correlation analyses identified eight metabolite-lipid metabolite modules, of which clusters rich in lysophosphatidylcholines (LPCs), lysophosphatidylethanolamines (LPEs), and diglycerides (DGs) were associated with increased risk of carotid plaque development. Functional annotation of microbial genes identified phospholipase A1 and A2 as key bacterial enzymes catalyzing reactions that generate these pro-atherogenic lipid species, providing a mechanistic link bridge between microbial metabolism and host vascular lipid regulation [26]. Collectively, metabolomic and metagenomic data reveal that atherosclerosis is influenced by a complex network of gut microbial metabolites that modulate host lipid, amino acid, and inflammatory pathways. Among these, TMAO, SCFAs, bile acids, lipopolysaccharides (LPS), phenylacetylglutamine (PAGln) represent the most well-established mediators of the gut microbiota-atherosclerosis axis [34–39], with more evidence implicating indole-3-propionate (IPA) and imidazole-propionate (ImP) [27, 40]. The following sections and the Fig. 1 discuss these key metabolites in greater mechanistic detail.Fig. 1Potential mechanisms for the association between gut microbiota and atherosclerosis. IL: Interleukin; LDL: Low-density lipoprotein (cholesterol); NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; TNF: Tumor necrosis factor; NLRP3: Nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) and pyrin domain-containing protein 3; FMO3: Flavin-dependent monooxygenase 3; PPFOR: Phenylpyruvate ferredoxin oxidoreductase; PPDC: Phenylpyruvate decarboxylase; mTOR: Mammalian target of rapamycin; Th: T helper cells; FXR: Farnesoid X receptor; PI3K-Akt: Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway; FOXO1: Forkhead box O1 Potential mechanisms for the association between gut microbiota and atherosclerosis. IL: Interleukin; LDL: Low-density lipoprotein (cholesterol); NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; TNF: Tumor necrosis factor; NLRP3: Nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) and pyrin domain-containing protein 3; FMO3: Flavin-dependent monooxygenase 3; PPFOR: Phenylpyruvate ferredoxin oxidoreductase; PPDC: Phenylpyruvate decarboxylase; mTOR: Mammalian target of rapamycin; Th: T helper cells; FXR: Farnesoid X receptor; PI3K-Akt: Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway; FOXO1: Forkhead box O1 TMAO TMAO is one of the most well-studied gut microbiota-derived metabolites consistently shown to be pro-atherogenic. It is generated through a two-step process linking diet, the gut microbiota, and host metabolism [41]. Dietary nutrients rich in trimethylamine (TMA) moieties, such as choline, L-carnitine, and betaine from red meat, eggs, and seafood, are first converted by gut bacteria including Escherichia, Clostridium, and Anaerococcus into TMA [34, 41]. TMA is then oxidized into TMAO by hepatic flavin-dependent monooxygenase 3 (FMO3) [41–43]. Both human and animal studies consistently show that elevated TMAO is positively associated with CVD and carotid intima-media thickness (i.e., an indicator of atherosclerotic burden) [41, 44]. Experimental models have shown that dietary choline or betaine increases macrophage foam cell formation, whereas suppression of gut microbiota markedly reduces this effect [41]. Inhibition of FMO3 by methimazole in mice has been shown to lower TMAO concentrations and significantly reduce carotid plaque area [44]. Mechanistically, TMAO upregulates pro-inflammatory cytokines such as interleukin (IL)-1β, tumor necrosis factor-α (TNF-α), and C-reactive protein via MAPK and nuclear factor (NF)-kB signaling pathways, thereby amplifying vascular inflammation, and it also activates Nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) and pyrin domain-containing protein 3 (NLRP3) inflammasome that further impair plaque stability [45]. Bile Acid Bile acids maybe another crucial link between gut microbiota and atherosclerosis, though their role remains complex and requires further investigation In the liver, cholesterol is converted into primary bile acids (cholic acid and chenodeoxycholic acid) through CYP enzyme-mediated reactions [46]. The gut microbiota modulates these processes by regulating CYP7A1, CYP7B1, and CYP27A1 expression. In the intestine, primary bile acids are deconjugated and converted into secondary bile acids (lithocholic acid, deoxycholic acid) by bacterial enzymes such as bile salt hydrolases and hydroxysteroid dehydrogenases, primarily expressed by Clostridium species [46–48]. Secondary bile acids act on the nuclear farnesoid X receptor (FXR) and the membrane receptor TGR5, influencing lipid, glucose, and inflammatory pathways [49]. FXR activation in the liver and intestine modulates triglyceride synthesis, very-low-density lipoprotein (VLDL) production, and reverse cholesterol transport, whereas TGR5 signaling can suppress inflammatory cytokine expression, promote cholesterol efflux, and regulate glucose metabolism by increasing incretin secretion [35, 50, 51]. However, the net impact of bile acid-mediated signaling on atherosclerosis remains controversial. Although FXR-deficient mice exhibit worsened plasma lipid profiles and increased atherosclerotic lesion formation, which supports a protective role for FXR, other studies have reported that FXR deletion reduces LDL cholesterol and plaque burden, suggesting that its effects may not be uniformly protective [52, 53]. Moreover, FXR is also expressed in vascular smooth muscle and endothelial cells, where it may directly modulate local inflammatory responses and plaque stability [54]. Overall, while bile acid metabolism has been found to influence FXR and TGR5 signaling, the directional of these effects on atherosclerosis remains unclear. SCFA SCFAs, including acetate, propionate, and butyrate, are key microbial fermentation products of dietary fiber, produced mainly by Bacteroides, Bifidobacterium, Eubacterium, and Lactobacillus [37, 55]. They maintain gut homeostasis and exhibit systemic cardioprotective effects. Acetate can transiently lower heart rate and blood pressure, while propionate improves lipid metabolism and immune regulation by enhancing T-regulatory cell function and IL-10 production, thereby lowering LDL and total cholesterol [56–58]. Butyrate suppresses NF-kB activity, enhances insulin sensitivity, reduces hepatic lipid accumulation, and prevents diet-induced atherosclerosis [59–61]. SCFAs also support colonocyte β-oxidation and contribute to the low pH environment of the gut lumen, maintaining anaerobic conditions that suppress pathogen growth and preserve beneficial anaerobes [62]. Collectively, these effects highlight the anti-inflammatory and metabolic benefits of SCFAs in vascular health. LPS LPS, an endotoxin derived from the outer membrane of Gram-negative bacteria, represents a key pro-inflammatory mediator linking dysbiosis to vascular injury [38]. Gut barrier disruption allows translocation of LPS into circulation, inducing chronic low-grade inflammation [63]. Once in the bloodstream, LPS binds to toll-like receptor 4 (TLR4) on endothelial cells and macrophages, activating NF-kB and NLRP3 inflammasome pathways and promoting secretion of IL-6, TNF-α, and IL-1β [63]. These cytokines enhance endothelial dysfunction, monocyte adhesion, and plaque formation. Both animal studies and human cohort studies have shown that circulating LPS levels are positively associated with CAS severity [64–67]. PAGln PAGln, a metabolite of phenylalanine catabolism, has recently emerged as another microbial driver of atherosclerosis [39]. In the gut, phenylalanine is converted by bacterial enzymes (i.e., phenylpyruvate decarboxylase [PPDC] and phenylpyruvate ferredoxin oxidoreductase [PPFOR]) into phenylacetic acid, which is then conjugated with glutamine in the liver to form PAGln [39]. Metagenomic studies demonstrated that genes encoding PPDC and PPFOR are enriched in the gut microbiota of patients with atherosclerotic disease [68]. PAGln activates adrenergic receptors on platelets, enhancing thrombosis and vascular inflammation, while also promoting oxidative stress and endothelial dysfunction [39, 69]. IPA IPA is a microbial-derived metabolite from tryptophan [70]. Emerging evidence has demonstrated its anti-atherogenic effects, and circulating levels of IPA were positively associated with high-fiber diets, likely through enrichment of IPA-producing gut microbiota [40, 70, 71]. The known IPA producers include Clostridium sporogenes, while other taxa such as Roseburia, Faecalibacterium, Eubacterium, and Lachnospira have shown positive associations with host circulating IPA levels in human studies [40, 72]. In the Women’s Interagency HIV Study (WIHS) cohort, plasma IPA was inversely associated with carotid plaque, independent of HIV serostatus [40]. In murine models, IPA supplementation reduced atherosclerotic plaque burden, lipid accumulation within plaques, and plasma total cholesterol and triglyceride levels [73]. Mechanistically, IPA inhibits macrophage foam cell formation by promoting reverse cholesterol transport, enhancing cholesterol efflux to apolipoprotein A-I (ApoA-I) through upregulation of ATP-binding cassette transporter A1 (ABCA1), without altering ABCG1 or SR-BI expression [73]. ImP ImP is a microbial-derived metabolite from histidine [74]. In the WIHS cohort, ImP was elevated in women with carotid plaque and inversely correlated with potentially beneficial bacterial species such as Roseburia inulinivorans and Johnsonella ignava [27]. Consistent findings were recently reported by another study that investigated potential mechanisms of ImP contributing to atherosclerosis [75]. ImP has been shown to promote atherosclerosis through activation of an imidazole-1 receptor (I1R)-mTOR signaling path in myeloid cells [75]. ImP supplementation in mouse models has been shown to increase aortic plaque burden without altering circulating cholesterol or glucose levels, and it induced expansion of pro-inflammatory immune cells such as Ly6Chi monocytes and T helper (Th) 1 and Th17 cells, as well as activated inflammatory and lipid metabolic pathways in macrophages, fibroblasts, and endothelial cells [75]. Additionally, recent evidence has shown that ImP impairs endothelial repair via PI3K-AKT inhibition and FOXO1 activation [76]. Microbial Functional Components, Proteomics, and Host Genetics Proteomics studies also support the link between gut microbiota and the biological mechanisms underlying atherogenesis. In the WIHS cohort, shotgun metagenomic and plasma proteomic profiling showed that microbial composition was closely connected to systemic inflammation and carotid plaque burden [27]. Pro-atherogenic taxa such as Fusobacterium nucleatum were positively associated with circulating inflammatory biomarkers (e.g., CXCLL9), while anti-atherogenic taxa, including SCFA-producing bacteria (e.g., Roseburia and Faecalibacterium), were inversely associated with inflammatory proteins CX3CL1 and LIF-R. Notably, adding plasma proteomic markers to statistical models attenuated associations between microbial taxa and carotid artery plaque, suggesting inflammation as a major mediator linking gut microbial dysbiosis to CAS [27]. Functional metagenomic analysis further revealed that the microbial gene repertoire is altered in CAS. In one of the first shotgun metagenomic analyses of patients with symptomatic CAS, Karlsson et al. demonstrated enrichment of peptidoglycan biosynthesis genes involved in proinflammatory bacterial functions, as well as depletion of phytoene dehydrogenase, a gene involved in β-carotene and carotenoid metabolism [19]. Patients also showed lower serum β-carotene levels, linking the microbial gene changes to host antioxidant status. These findings suggest that functional shifts within the gut microbiome toward proinflammation, despite an enrichment in butyrate-producing bacteria such as Clostridium spp. [19]. Beyond inflammation, large population-based proteomic analyses have demonstrated that gut microbiota is linked to host neuroendocrine proteins. In the LifeLines-DEEP cohort of over 1,000 Dutch adults, microbial diversity was associated with fecal Chromogranin A (CgA), which is a neuroendocrine peptide released by enteroendocrine cells that reflects mucosal immune activation and epithelial integrity [76, 77]. Individuals with lower CgA exhibited a more diverse and metabolically favorable microbiome [77]. Complementary evidence from the LifeLines-DEEP systems-genomic study further revealed that host genetics and gut microbiota had additive effects on circulating proteins related to cardiovascular disease, collectively explaining up to 77% of inter-individual variation. Notably, microbial features were most strongly linked to proteins for lipid metabolism and fibrinolysis, such as PON3 that links to HDL level and suppresses LDL oxidation in the blood and showed the strongest association to α- and β-diversity, and plasminogen activator inhibitor (PAI)-1 [78]. These findings underscore the integrated host-microbe regulation of vascular and metabolic homeostasis. Consistently, an integrated multi-omics study of CAS combined 16S rRNA sequencing, untargeted metabolomics, and transcriptomics to identify a coordinated microbiota-metabolite-gene network [16]. Patients with CAS displayed an upregulation of FABP4 gene expression that encodes fatty acid binding protein 4, which is involved in macrophage activation and lipid metabolism in atherosclerosis [79]. Notably, FABP4 expression was also correlated with Acidaminococcus and PAGln, suggesting a potential gut microbial influence on lipid metabolism and inflammation via the interplay between microbiota, metabolites, and host genetics [16]. Together, these findings show how genetic, microbial, proteomics, and transcriptomics converge to implicate CAS risk and progression. Other Modifying Factors The relationship between the gut microbiome and ACVD is modulated by a range of other factors, such as sex, age, and diet. Females and males differ not only in cardiovascular physiology but also in their gut microbial composition and metabolite production [79, 80]. It has been shown that females have higher levels of Bifidobacterium, Ruminococcus, and Akkermansia, while males have higher abundance of Prevotella, Megamonas, and Fusobacterium [81]. Emerging evidence indicates that sex hormones actively shape the gut microbiome, because no sex difference was observed in early childhood or until puberty, likely due that gonadal hormones have not been initiated [82]. For example, it has been shown that estrogen promotes the growth of Akkermansia, which produces SCFAs, and Prevotella was found to be positively associated with testosterone levels [83]. Sex has also been shown to differentially impact the TMAO synthesis, where both the expression of FMO3, which is the key microbial enzyme that converts TMA to TMAO, is higher in females and males in both human and mouse studies, and the plasma level of TMAO in female has also been shown higher than males in mouse studies [8]. These sex-differences in gut microbial composition and metabolite production may contribute to variations in atherosclerosis susceptibility between males and females. Male-enriched taxa such as Fusobacterium have been linked to proinflammatory pathways and altered lipid metabolism, whereas female-enriched SCFA-producing bacteria may confer partial protection through anti-inflammatory effects [84]. Moreover, given that TMAO is a well-known player in atherosclerosis pathophysiology, sex-differences in TMAO synthesis and metabolism could further explain the observed difference in atherosclerosis risk. Aging comes with a gradual decline in gut microbial diversity and a shift toward taxa associated with inflammation and metabolic dysfunction. As people age, gut microbiota diversity tends to decrease [85]. However, exceptionally long-lived individuals with age above 100 years old often retain high microbial diversity and abundance of health-associated taxa including Christensenellaceae, Lachnospiraceae, Ruminococcaceae, and Akkermansia, which primarily produce SCFAs [85]. Importantly, dietary intervention can mitigate age-related microbial deterioration. In the large multicenter NU-AGE trial, a one-year Mediterranean diet intervention in older adults across five European countries led to increased abundance of beneficial SCFA-producing bacteria and reduced inflammatory markers like C-reactive protein and IL-17 [86]. Participants with greater adherence to the Mediterranean diet showed improved frailty scores and cognitive function, suggesting that targeted dietary modulation of the gut microbiota may promote healthier aging and reduce inflammation-linked vascular risk [86]. Research Gaps and Future Directions Although substantial evidence now links gut microbial dysbiosis and microbially derived metabolites with atherosclerosis, critical knowledge gaps remain before these findings can be translated into clinical interventions. Current studies are largely cross-sectional, limiting causal inference. Future research should prioritize longitudinal and interventional study designs integrating microbial metagenomics and metabolomics together with host multi-omics and clinical characteristics to delineate causal relationships between microbiome alterations and plaque development, particularly in CAS, which directly contributes to ischemic stroke risk. Probiotics may be a potential approach to modulate atherosclerosis-related dysbiosis, but the responses to probiotics or potential metabolite drug candidates depend heavily on an individual’s baseline microbiome, metabolic profile, inflammatory state, dietary intake, and medication use. Future studies should determine whether precision interventions, such as stratifying individuals by their gut microbiota types, diversities, and metabolite profiles, are feasible and clinically meaningful. Given the heterogeneity in responses to probiotics, integrating host- and microbiome-specific information into intervention design might be informative. Combining dietary modulation with targeted microbial or metabolic interventions may offer a precision-medicine approach to atherosclerosis prevention [62]. Also, because probiotic effects are strain-specific, future work should determine and validate which strains have metabolic or immunomodulatory effects to atherosclerosis. Fecal microbiota transplantation (FMT) has been shown to restore microbial diversity in conditions like Clostridioides difficile infection, but its application to atherosclerosis remains underexplored. Evidence from mouse studies shows that transferring the gut microbiota from healthy wild-type donors into atherosclerosis-prone mice can attenuate carotid plaque formation [87]. However, in cardiometabolic diseases, FMT has generally produced modest, transient, and highly variable effects [62]. Future research should determine whether more targeted or optimized FMT approaches can produce durable and reproducible benefits specifically for atherosclerosis. Emerging metabolites, such as ImP, may be a novel therapeutic target. Elevated ImP has been consistently observed in individuals with insulin resistance and type 2 diabetes [74]. Recent mechanistic studies demonstrate that ImP promotes atherosclerosis through activation of imidazole-1 receptor in myeloid cells, suggesting a new metabolic-immune axis in vascular damage [75]. Future studies should investigate whether targeting ImP signaling can reduce cardiometabolic and atherosclerotic risk, particularly among individuals with metabolic disorders or those treated with GLP-1 receptor agonists. This is especially relevant because the prevalence of GLP-1 utilization has been increasing, and ImP has been shown to impair the glucose-lowering efficacy of metformin, a drug, like GLP-1 RAs, improves insulin sensitivity [86, 87]. Hyperlipidemia represents another promising area for microbiome-targeted therapy. Clinical and preclinical studies show that probiotic and symbiotic supplementation, such as those with Lactobacillus and Bifidobacterium, can improve lipid profiles [62]. However, these studies are often limited by small sample sizes, short intervention durations, and inconsistent formulations, and therefore larger randomized controlled trials are needed to establish efficacy, optimizing dosing, and assess long-term effects and safety. Beyond probiotics, pharmacologic inhibition of microbial enzymes may also be a translational route. For instance, non-lethal inhibition of TMA lyase, which is the enzyme responsible for the first step in TMAO production from dietary choline, has been shown in animal models to prevent macrophage foam cell formation and reduce plaque burden without altering cholesterol levels [88]. However, such promising results still need to be validated in human trials. Similarly, bile acid-responsive receptors like FXR have emerged as a potential therapeutic target, but contradictory evidence has been shown for its role on atherosclerosis, and thus more research is needed [89]. Microbiota-derived metabolites could also serve as novel biomarkers for early detection of CAS. As shown in recent multi-omics studies, urinary metabolites can outperform microbial taxonomy alone in distinguishing individuals with carotid plaque, highlighting the diagnostic potential of metabolomic signatures [14]. Standardizing and pipelining the analytical methods for metabolite profiling and integrating these data with host genetics and proteomics may accelerate translating these findings into clinical applications for risk stratification. Conclusion Accumulating evidence indicates that the gut microbiota can act as both a modulator and a biomarker of ACVD. Microbial dysbiosis may contribute to ACVD pathogenesis through multiple mechanisms, most notably via microbiota-derived metabolites that influence endothelial function, systemic inflammation, and lipid metabolism. Alterations in the abundance of specific microbial taxa, characterized by enrichment of pro-inflammatory species and depletion of anti-inflammatory, SCFA-producing bacteria, further underscore the microbiota’s mechanistic involvement in vascular injury. Despite these advances, considerable heterogeneity persists across studies. Future longitudinal and interventional research integrating metagenomics and host multi-omics is essential to clarify causal relationships and identify clinically actionable targets. With further evidence, leveraging microbiome-based biomarkers and interventions, potentially through personalized nutrition, probiotics, or modulation of specific microbial functional enzymes, may enable precision prevention and treatment strategies for ACVD and broader cardiovascular diseases. Key References Ji L, Chen S, Gu G, Zhou J, Wang W, Ren J, et al. Exploration of Crucial Mediators for Carotid Atherosclerosis Pathogenesis Through Integration of Microbiome, Metabolome, and Transcriptome. Front Physiol. 2021;12:645212. 10.3389/fphys.2021.645212○ This study integrated microbiome, metabolome, and transcriptome analyses to provide mechanistic insight into the link between gut microbiota and carotid atherosclerosis.Szabo H, Hernyes A, Piroska M, Ligeti B, Fussy P, Zoldi L, et al. Association between Gut Microbial Diversity and Carotid Intima-Media Thickness. Medicina (Kaunas). 2021;57:195. 10.3390/medicina57030195○ This study used monozygotic twins to control for genetic factors and demonstrated gut microbial alterations associated with increased carotid intima-media thickness, highlighting a potential microbial contribution to subclinical atherosclerosis.Zhu S, Xu K, Jiang Y, Zhu C, Suo C, Cui M, et al. The gut microbiome in subclinical atherosclerosis: a population-based multiphenotype analysis. Rheumatology (Oxford). 2022;61:258–69. 10.1093/rheumatology/keab309○ This large population-based study characterized gut microbiome features associated with subclinical atherosclerosis across multiple phenotypes, demonstrating that microbial composition and diversity were linked to carotid plaque and vascular risk profiles in asymptomatic individuals.Wang Z, Peters BA, Usyk M, Xing J, Hanna DB, Wang T, et al. Gut Microbiota, Plasma Metabolomic Profiles, and Carotid Artery Atherosclerosis in HIV Infection. Arteriosclerosis, Thrombosis, and Vascular Biology. Lippincott Williams & WilkinsHagerstown, MD; 2022; 10.1161/ATVBAHA.121.317276○ This study integrated gut microbiome and plasma metabolomics data and revealed that specific gut microbes were associated with altered lipid metabolism and carotid artery atherosclerosis, highlighting a potential microbe-lipid-atherosclerosis axis.Wang Z, Peters BA, Bryant M, Hanna DB, Schwartz T, Wang T, et al. Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection. Microbiome. 2023;11:119. 10.1186/s40168-023-01566-2○ This paper integrated microbiome, metabolome, and proteomic inflammation marker data, identified specific gut bacterial species, as well as the microbial metabolite imidazole propionate (ImP), that were associated with carotid artery atherosclerosis, potentially through mechanisms involving host immune activation and inflammation.Luo K, Wang Z, Peters BA, Hanna DB, Wang T, Sollecito CC, et al. Tryptophan metabolism, gut microbiota, and carotid artery plaque in women with and without HIV infection. AIDS. 2024;38:223–33. 10.1097/QAD.0000000000003596○ This study provided evidence showing that higher levels of indole-3-propionate (IPA) were inversely associated with carotid artery plaque and also reported the gut microbial species related to IPA production.Mastrangelo A, Robles-Vera I, Mañanes D, Galán M, Femenía-Muiña M, Redondo-Urzainqui A, et al. Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nature. Nature Publishing Group; 2025;645:254–61. 10.1038/s41586-025-09263-w○ This study provided the most recent evidence showing that circulating imidazole propionate levels are associated with coronary artery diseases, suggesting its potential as both a biomarker and a therapeutic effect. Ji L, Chen S, Gu G, Zhou J, Wang W, Ren J, et al. Exploration of Crucial Mediators for Carotid Atherosclerosis Pathogenesis Through Integration of Microbiome, Metabolome, and Transcriptome. Front Physiol. 2021;12:645212. 10.3389/fphys.2021.645212○ This study integrated microbiome, metabolome, and transcriptome analyses to provide mechanistic insight into the link between gut microbiota and carotid atherosclerosis. Ji L, Chen S, Gu G, Zhou J, Wang W, Ren J, et al. Exploration of Crucial Mediators for Carotid Atherosclerosis Pathogenesis Through Integration of Microbiome, Metabolome, and Transcriptome. Front Physiol. 2021;12:645212. 10.3389/fphys.2021.645212○ This study integrated microbiome, metabolome, and transcriptome analyses to provide mechanistic insight into the link between gut microbiota and carotid atherosclerosis. ○ This study integrated microbiome, metabolome, and transcriptome analyses to provide mechanistic insight into the link between gut microbiota and carotid atherosclerosis. ○ This study integrated microbiome, metabolome, and transcriptome analyses to provide mechanistic insight into the link between gut microbiota and carotid atherosclerosis. Szabo H, Hernyes A, Piroska M, Ligeti B, Fussy P, Zoldi L, et al. Association between Gut Microbial Diversity and Carotid Intima-Media Thickness. Medicina (Kaunas). 2021;57:195. 10.3390/medicina57030195○ This study used monozygotic twins to control for genetic factors and demonstrated gut microbial alterations associated with increased carotid intima-media thickness, highlighting a potential microbial contribution to subclinical atherosclerosis. Szabo H, Hernyes A, Piroska M, Ligeti B, Fussy P, Zoldi L, et al. Association between Gut Microbial Diversity and Carotid Intima-Media Thickness. Medicina (Kaunas). 2021;57:195. 10.3390/medicina57030195○ This study used monozygotic twins to control for genetic factors and demonstrated gut microbial alterations associated with increased carotid intima-media thickness, highlighting a potential microbial contribution to subclinical atherosclerosis. ○ This study used monozygotic twins to control for genetic factors and demonstrated gut microbial alterations associated with increased carotid intima-media thickness, highlighting a potential microbial contribution to subclinical atherosclerosis. ○ This study used monozygotic twins to control for genetic factors and demonstrated gut microbial alterations associated with increased carotid intima-media thickness, highlighting a potential microbial contribution to subclinical atherosclerosis. Zhu S, Xu K, Jiang Y, Zhu C, Suo C, Cui M, et al. The gut microbiome in subclinical atherosclerosis: a population-based multiphenotype analysis. Rheumatology (Oxford). 2022;61:258–69. 10.1093/rheumatology/keab309○ This large population-based study characterized gut microbiome features associated with subclinical atherosclerosis across multiple phenotypes, demonstrating that microbial composition and diversity were linked to carotid plaque and vascular risk profiles in asymptomatic individuals. Zhu S, Xu K, Jiang Y, Zhu C, Suo C, Cui M, et al. The gut microbiome in subclinical atherosclerosis: a population-based multiphenotype analysis. Rheumatology (Oxford). 2022;61:258–69. 10.1093/rheumatology/keab309○ This large population-based study characterized gut microbiome features associated with subclinical atherosclerosis across multiple phenotypes, demonstrating that microbial composition and diversity were linked to carotid plaque and vascular risk profiles in asymptomatic individuals. ○ This large population-based study characterized gut microbiome features associated with subclinical atherosclerosis across multiple phenotypes, demonstrating that microbial composition and diversity were linked to carotid plaque and vascular risk profiles in asymptomatic individuals. ○ This large population-based study characterized gut microbiome features associated with subclinical atherosclerosis across multiple phenotypes, demonstrating that microbial composition and diversity were linked to carotid plaque and vascular risk profiles in asymptomatic individuals. Wang Z, Peters BA, Usyk M, Xing J, Hanna DB, Wang T, et al. Gut Microbiota, Plasma Metabolomic Profiles, and Carotid Artery Atherosclerosis in HIV Infection. Arteriosclerosis, Thrombosis, and Vascular Biology. Lippincott Williams & WilkinsHagerstown, MD; 2022; 10.1161/ATVBAHA.121.317276○ This study integrated gut microbiome and plasma metabolomics data and revealed that specific gut microbes were associated with altered lipid metabolism and carotid artery atherosclerosis, highlighting a potential microbe-lipid-atherosclerosis axis. Wang Z, Peters BA, Usyk M, Xing J, Hanna DB, Wang T, et al. Gut Microbiota, Plasma Metabolomic Profiles, and Carotid Artery Atherosclerosis in HIV Infection. Arteriosclerosis, Thrombosis, and Vascular Biology. Lippincott Williams & WilkinsHagerstown, MD; 2022; 10.1161/ATVBAHA.121.317276○ This study integrated gut microbiome and plasma metabolomics data and revealed that specific gut microbes were associated with altered lipid metabolism and carotid artery atherosclerosis, highlighting a potential microbe-lipid-atherosclerosis axis. ○ This study integrated gut microbiome and plasma metabolomics data and revealed that specific gut microbes were associated with altered lipid metabolism and carotid artery atherosclerosis, highlighting a potential microbe-lipid-atherosclerosis axis. ○ This study integrated gut microbiome and plasma metabolomics data and revealed that specific gut microbes were associated with altered lipid metabolism and carotid artery atherosclerosis, highlighting a potential microbe-lipid-atherosclerosis axis. Wang Z, Peters BA, Bryant M, Hanna DB, Schwartz T, Wang T, et al. Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection. Microbiome. 2023;11:119. 10.1186/s40168-023-01566-2○ This paper integrated microbiome, metabolome, and proteomic inflammation marker data, identified specific gut bacterial species, as well as the microbial metabolite imidazole propionate (ImP), that were associated with carotid artery atherosclerosis, potentially through mechanisms involving host immune activation and inflammation. Wang Z, Peters BA, Bryant M, Hanna DB, Schwartz T, Wang T, et al. Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection. Microbiome. 2023;11:119. 10.1186/s40168-023-01566-2○ This paper integrated microbiome, metabolome, and proteomic inflammation marker data, identified specific gut bacterial species, as well as the microbial metabolite imidazole propionate (ImP), that were associated with carotid artery atherosclerosis, potentially through mechanisms involving host immune activation and inflammation. ○ This paper integrated microbiome, metabolome, and proteomic inflammation marker data, identified specific gut bacterial species, as well as the microbial metabolite imidazole propionate (ImP), that were associated with carotid artery atherosclerosis, potentially through mechanisms involving host immune activation and inflammation. ○ This paper integrated microbiome, metabolome, and proteomic inflammation marker data, identified specific gut bacterial species, as well as the microbial metabolite imidazole propionate (ImP), that were associated with carotid artery atherosclerosis, potentially through mechanisms involving host immune activation and inflammation. Luo K, Wang Z, Peters BA, Hanna DB, Wang T, Sollecito CC, et al. Tryptophan metabolism, gut microbiota, and carotid artery plaque in women with and without HIV infection. AIDS. 2024;38:223–33. 10.1097/QAD.0000000000003596○ This study provided evidence showing that higher levels of indole-3-propionate (IPA) were inversely associated with carotid artery plaque and also reported the gut microbial species related to IPA production. Luo K, Wang Z, Peters BA, Hanna DB, Wang T, Sollecito CC, et al. Tryptophan metabolism, gut microbiota, and carotid artery plaque in women with and without HIV infection. AIDS. 2024;38:223–33. 10.1097/QAD.0000000000003596○ This study provided evidence showing that higher levels of indole-3-propionate (IPA) were inversely associated with carotid artery plaque and also reported the gut microbial species related to IPA production. ○ This study provided evidence showing that higher levels of indole-3-propionate (IPA) were inversely associated with carotid artery plaque and also reported the gut microbial species related to IPA production. ○ This study provided evidence showing that higher levels of indole-3-propionate (IPA) were inversely associated with carotid artery plaque and also reported the gut microbial species related to IPA production. Mastrangelo A, Robles-Vera I, Mañanes D, Galán M, Femenía-Muiña M, Redondo-Urzainqui A, et al. Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nature. Nature Publishing Group; 2025;645:254–61. 10.1038/s41586-025-09263-w○ This study provided the most recent evidence showing that circulating imidazole propionate levels are associated with coronary artery diseases, suggesting its potential as both a biomarker and a therapeutic effect. Mastrangelo A, Robles-Vera I, Mañanes D, Galán M, Femenía-Muiña M, Redondo-Urzainqui A, et al. Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nature. Nature Publishing Group; 2025;645:254–61. 10.1038/s41586-025-09263-w○ This study provided the most recent evidence showing that circulating imidazole propionate levels are associated with coronary artery diseases, suggesting its potential as both a biomarker and a therapeutic effect. ○ This study provided the most recent evidence showing that circulating imidazole propionate levels are associated with coronary artery diseases, suggesting its potential as both a biomarker and a therapeutic effect. ○ This study provided the most recent evidence showing that circulating imidazole propionate levels are associated with coronary artery diseases, suggesting its potential as both a biomarker and a therapeutic effect.